Literature DB >> 31101738

Suicide and suicide attempts after subthalamic nucleus stimulation in Parkinson disease.

Giulia Giannini1, Matthieu Francois1, Eugénie Lhommée1, Mircea Polosan1, Emmanuelle Schmitt1, Valérie Fraix1, Anna Castrioto1, Claire Ardouin1, Amélie Bichon1, Pierre Pollak1, Alim-Louis Benabid1, Eric Seigneuret1, Stephan Chabardes1, Maxime Wack1, Paul Krack1, Elena Moro2.   

Abstract

OBJECTIVE: To determine the postoperative attempted and completed suicide rates after subthalamic nucleus deep brain stimulation (STN-DBS) in a single-center cohort and to determine factors associated with attempted and completed suicide.
METHODS: We retrospectively included all patients with Parkinson disease (PD) who underwent bilateral STN-DBS surgery at the Grenoble University Hospital between 1993 and 2016. For each patient who committed or attempted suicide, 2 patients with PD with STN-DBS without any suicidal behaviors were matched for age (±1 year), sex, and year of surgery (±2 years). Clinical data were collected from medical records. Detailed preoperative and postoperative neuropsychological evaluations, including frontal and Beck Depression Inventory (BDI) scores, were gathered.
RESULTS: A total of 534 patients with PD were included. Completed and attempted suicide percentages were 0.75% (4 of 534) and 4.11% (22 of 534), respectively. The observed suicide rate in the first postoperative year (187.20 of 100,000 per year, 1 of 534) was higher than the expected National Observatory on Suicide Risks rate adjusted for age and sex (standardized mortality ratio 8.1). This rate remained similar over the second and third postoperative years. In a comparison of the 26 patients completing/attempting suicide and the 52 controls, the first group showed more frequent history of suicidal ideation/suicide attempts and psychotic symptoms, higher percentage of family psychiatric history, higher psychiatric medication use, and higher preoperative frontal and BDI scores on neuropsychological evaluations.
CONCLUSIONS: Suicide behaviors can occur after STN-DBS, especially during the first 3 years. A careful multidisciplinary assessment and long-term follow-up are recommended to recognize and treat this potentially preventable risk for mortality.
© 2019 American Academy of Neurology.

Entities:  

Mesh:

Year:  2019        PMID: 31101738     DOI: 10.1212/WNL.0000000000007665

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

Review 1.  Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease: A Meta-Analysis of Mood Effects.

Authors:  Tomas Cartmill; David Skvarc; Richard Bittar; Jane McGillivray; Michael Berk; Linda K Byrne
Journal:  Neuropsychol Rev       Date:  2021-02-19       Impact factor: 7.444

Review 2.  Depression in Patients with Parkinson's Disease: Current Understanding of its Neurobiology and Implications for Treatment.

Authors:  Stéphane Prange; Hélène Klinger; Chloé Laurencin; Teodor Danaila; Stéphane Thobois
Journal:  Drugs Aging       Date:  2022-06-16       Impact factor: 4.271

3.  Parkinson's Disease-Related Risk of Suicide and Effect of Deep Brain Stimulation: Meta-Analysis.

Authors:  Juncong Du; Xi Liu; Xuan Zhou; Hui Wang; Wen Zhou; Jin Jiang; Wuxue Peng; Lijuan Mo; Changhong Tan; Lifen Chen
Journal:  Parkinsons Dis       Date:  2020-09-27

Review 4.  Management of psychiatric disorders in Parkinson's disease : Neurotherapeutics - Movement Disorders Therapeutics.

Authors:  Daniel Weintraub
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

5.  Etiopathogenesis of Suicide: A Conceptual Analysis of Risk and Prevention Within a Comprehensive, Deterministic Model.

Authors:  Jack C Lennon
Journal:  Front Psychol       Date:  2019-09-12

6.  Deep brain stimulation of the subthalamic nucleus in obsessive-compulsives disorders: long-term follow-up of an open, prospective, observational cohort.

Authors:  Stephan Chabardes; Paul Krack; Brigitte Piallat; Thierry Bougerol; Eric Seigneuret; Jerome Yelnik; Sara Fernandez Vidal; Olivier David; Luc Mallet; Alim-Louis Benabid; Mircea Polosan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-10-08       Impact factor: 10.154

7.  Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's Disease.

Authors:  Marina Picillo; Onanong Phokaewvarangkul; Yu-Yan Poon; Cameron C McIntyre; Sinem Balta Beylergil; Renato P Munhoz; Suneil K Kalia; Mojgan Hodaie; Andres M Lozano; Alfonso Fasano
Journal:  Mov Disord       Date:  2020-11-09       Impact factor: 10.338

8.  Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease.

Authors:  Stefanie T Jost; Veerle Visser-Vandewalle; Alexandra Rizos; Philipp A Loehrer; Monty Silverdale; Julian Evans; Michael Samuel; Jan Niklas Petry-Schmelzer; Anna Sauerbier; Alexandra Gronostay; Michael T Barbe; Gereon R Fink; Keyoumars Ashkan; Angelo Antonini; Pablo Martinez-Martin; K Ray Chaudhuri; Lars Timmermann; Haidar S Dafsari
Journal:  NPJ Parkinsons Dis       Date:  2021-06-08

9.  Deep brain stimulation of the Cuneiform nucleus for levodopa-resistant freezing of gait in Parkinson's disease: study protocol for a prospective, pilot trial.

Authors:  Stephano J Chang; Iahn Cajigas; James D Guest; Brian R Noga; Eva Widerström-Noga; Ihtsham Haq; Letitia Fisher; Corneliu C Luca; Jonathan R Jagid
Journal:  Pilot Feasibility Stud       Date:  2021-06-02

10.  A Systematic Review of Neuromodulation Treatment Effects on Suicidality.

Authors:  Mehmet Utku Kucuker; Ammar G Almorsy; Ayse Irem Sonmez; Anna N Ligezka; Deniz Doruk Camsari; Charles P Lewis; Paul E Croarkin
Journal:  Front Hum Neurosci       Date:  2021-06-25       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.